SARS CoV-2 Infection and Inflammatory Biomarkers

Sponsor
University of Thessaly (Other)
Overall Status
Completed
CT.gov ID
NCT05145751
Collaborator
(none)
115
1
10
11.5

Study Details

Study Description

Brief Summary

Early research suggests that inflammation plays a key role in the development of SARS CoV-2 infection. The immune response to respiratory infection is characterized by an influx of neutrophils to the lungs. This study ought to investigate the association of simple biomarkers such as NLR and PLR with the clinical outcome in SARS CoV-2 infection patients.

Condition or Disease Intervention/Treatment Phase
  • Other: Simple inflammatory biomarkers measurement

Detailed Description

Early research suggests that inflammation plays a key role in the development of SARS CoV-2 infection. The immune response to respiratory infection is characterized by an influx of neutrophils to the lungs. Moreover, previous studies have demonstrated that a sustained release of anti-inflammatory cytokines may lead to high levels of circulating neutrophils and lymphocytes' apoptosis with subsequent lymphopenia and immune response imbalance. Therefore, circulating biomarkers that represent inflammation and immune status could serve as potential predictors for the prognosis of SARS CoV-2 patients. The neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) are cheap and simply calculated biomarkers which have been identified as markers of systemic inflammation, severity of the disease and prognosis in several patient populations.

This study ought to investigate the association of simple biomarkers such as NLR and PLR with the clinical outcome in SARS CoV-2 infection patients.

Study Design

Study Type:
Observational
Actual Enrollment :
115 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
SARS CoV-2 Infection and Simple Inflammatory Biomarkers.
Actual Study Start Date :
Apr 1, 2021
Actual Primary Completion Date :
Oct 1, 2021
Actual Study Completion Date :
Jan 31, 2022

Arms and Interventions

Arm Intervention/Treatment
COVID-19 infection

Consecutive patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection

Other: Simple inflammatory biomarkers measurement
In patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection the values of simple inflammatory biomarkers such NLR will be measured
Other Names:
  • Consecutive patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection
  • Outcome Measures

    Primary Outcome Measures

    1. Outcome [1 year]

      Outcome after COVID-19 infection

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Consecutive patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection
    Exclusion Criteria:
    • Patients aged<18 years

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Univeristy of Thessaly Larissa Thessaly Greece 41110

    Sponsors and Collaborators

    • University of Thessaly

    Investigators

    • Study Chair: Eleni Arnaoutoglou, M.D., Ph.D., Study Chair

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Elena Arnaoutoglou, Professor of Anesthesiology, University of Thessaly
    ClinicalTrials.gov Identifier:
    NCT05145751
    Other Study ID Numbers:
    • 46937
    First Posted:
    Dec 6, 2021
    Last Update Posted:
    Mar 2, 2022
    Last Verified:
    Mar 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Elena Arnaoutoglou, Professor of Anesthesiology, University of Thessaly
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 2, 2022